Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Faecal microbiota transplantation increases activity of immunotherapy in mRCC

ESMO 2024

13 - 17 Sep 2024

Published: 16 Sep 2024

Views: 71

Rating:

Save

Dr Chiara Ciccarese - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy

Dr Chiara Ciccarese talks to ecancer at ESMO 2024 about data she presented from the randomized phase II TACITO trial.

This looked at faecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma.

The preliminary results of TACITO trial show for the first time the role of FMT in increasing the activity of immune checkpoint inhibitor based therapies in metastatic renal cell carcinoma patients.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

ESMO 2024: Latest in bladder cancer - expert review

Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van...

ESMO 2024: Latest in bladder cancer - expert review ( Dr Patrizia Giannatemp, Prof Andrea Necchi, Prof Simon Crabb, Dr Michiel Van Der Heijden )

ESMO 2024: Latest updates in mRCC

Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane...

ESMO 2024: Latest updates in mRCC ( Dr Javier Puente, Dr Guillermo De Velasco, Dr Cristina Suárez and Prof Stéphane Oudard )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Bladder cancer updates from the first half of 2024

Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo

Bladder cancer updates from the first half of 2024 ( Prof Alison Birtle, Dr Ignacio Durán, Dr Patrizia Giannatempo )

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic...

Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA

Enfortumab vedotin improves efficacy outcomes in locally advanced or metastatic urothelial cancer across all exposure quartiles ( Prof Daniel Petrylak - Yale School of Medicine, New Haven, USA )

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed...

Prof Thierry Facon - Chu De Lille, Lille, France

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Thierry Facon - Chu De Lille, Lille, France )

Manageable safety profile with early efficacy of Tec-DR in NDMM

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive...

Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer ( Dr Antonio Cigliola - IRCCS San Raffaele Hospital, Milan, Italy )

More from ecancer